ArticleJournal of lipid research2014
Longitudinal changes in tear fluid lipidome brought about by eyelid-warming treatment in a cohort of meibomian gland dysfunction.
Article in Journal of lipid research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- Article
- Mechanisms and Safety of Therapeutic Strategies in Meibomian Gland Dysfunction: A Narrative Review.Ophthalmic research · 2026Review
- Differential Tear Lipid Metabolomics Signatures Discriminate Superior Limbic Keratoconjunctivitis From Dry Eye Disease.Translational vision science & technology · 2025Article
- Identification of tear lipid biomarkers in women with dry eye disease and the impact of intense pulsed light therapy: a case-control study.BMC ophthalmology · 2025Observational
- Article
- Effectiveness and safety of a thermo-mechanical action device versus thermal pulsation device in the treatment of meibomian gland dysfunction.Journal of cataract and refractive surgery · 2024Article
- Changes in Human Meibum Lipid Composition Related to the Presence and Severity of Meibomian Gland Dysfunction.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2024Article
- Decipher 'Em All: A Profiling Study on the Effects of Acyl Groups inLangmuir : the ACS journal of surfaces and colloids · 2024Article
- Meibography signal intensity as a novel image biomarker for meibomian gland function: evidence from cross-sectional and longitudinal analyses.Quantitative imaging in medicine and surgery · 2024Article
- Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape.Ophthalmology and therapy · 2023Review
- The role of sphingolipids in meibomian gland dysfunction and ocular surface inflammation.The ocular surface · 2022Review
- Human meibum and tear film derived cholesteryl and wax esters in meibomian gland dysfunction and tear film structure.The ocular surface · 2022Article
- Lipidomics Profiles Revealed Alterations in Patients With Meibomian Gland Dysfunction After Exposure to Intense Pulsed Light.Frontiers in neurology · 2022Article
- Human Meibum and Tear Film Derived (O-Acyl)-Omega-Hydroxy Fatty Acids as Biomarkers of Tear Film Dynamics in Meibomian Gland Dysfunction and Dry Eye Disease.Investigative ophthalmology & visual science · 2021Article
- Human meibum and tear film derived (O-acyl)-omega-hydroxy fatty acids in meibomian gland dysfunction.The ocular surface · 2021Article
- Lipidomics Analysis of the Tears in the Patients Receiving LASIK, FS-LASIK, or SBK Surgery.Frontiers in medicine · 2021Article
- Non-pharmaceutical treatment options for meibomian gland dysfunction.Clinical & experimental optometry · 2020Review
- Comprehensive profiling of Asian and Caucasian meibomian gland secretions reveals similar lipidomic signatures regardless of ethnicity.Scientific reports · 2020Article
- Analytical separations for lipids in complex, nonpolar lipidomes using differential mobility spectrometry.Journal of lipid research · 2019Article
- Dry Eye Disease: Emerging Approaches to Disease Analysis and Therapy.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye and ocular discomfort characterized by an unstable tear film principally attributed to afflicted delivery of lipids to the ocular surface. Herein, we elucidated longitudinal tear lipid alterations associated with disease alleviation and symptom improvement in a cohort of MGD patients undergoing eyelid-warming treatment for 12 weeks. Remarkably, eyelid-warming resulted in stark reductions in lysophospholipids (P < 0.001 for lyso-plasmalogen phosphatidylethanolamine, lysophosphatidylcholine, and lysophosphatidylinositol), as well as numerous PUFA-containing diacylglyceride species in tears, accompanied by significant increases in several PUFA-containing phospholipids. These changes in tear lipidomes suggest that eyelid-warming leads to diminished activity of tear phospholipases that preferentially target PUFA-containing phospholipids. In addition, treatment led to appreciable increases (P < 0.001) in O-acyl-ω-hydroxy-FAs (OAHFAs), which are lipid amphiphiles critical to the maintenance of tear film stability. Longitudinal changes in the tear lipids aforementioned also significantly (P < 0.05) correlated with reduced rate of ocular evaporation and improvement in ocular symptoms. The foregoing data thus indicate that excess ocular surface phospholipase activity detrimental to tear film stability could be alleviated by eyelid warming alone without application of steroids and identify tear OAHFAs as suitable markers to monitor treatment response in MGD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.